|
1
|
Naora H and Montell DJ: Ovarian cancer
metastasis: integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lesley J, Hyman R and Kincade PW: CD44 and
its interaction with extracellular matrix. Adv Immunol. 54:271–335.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aruffo A, Stamenkovic I, Melnick M,
Underhill CB and Seed B: CD44 is the principal cell surface
receptor for hyaluronate. Cell. 61:1303–1313. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li C, Heidt DG, Dalerba P, et al:
Identification of pancreatic cancer stem cells. Cancer Res.
67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takaishi S, Okumura T, Tu S, et al:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Günthert U, Stauder R, Mayer B, Terpe HJ,
Finke L and Friedrichs K: Are CD44 variant isoforms involved in
human tumour progression? Cancer Surv. 24:19–42. 1995.PubMed/NCBI
|
|
9
|
Rall CJ and Rustgi AK: CD44 isoform
expression in primary and metastatic pancreatic adenocarcinoma.
Cancer Res. 55:1831–1835. 1995.PubMed/NCBI
|
|
10
|
Chen GY and Wang DR: The expression and
clinical significance of CD44v in human gastric cancers. World J
Gastroenterol. 6:125–127. 2000.
|
|
11
|
Orian-Rousseau V, Chen L, Sleeman JP,
Herrlich P and Ponta H: CD44 is required for two consecutive steps
in HGF/c-Met signaling. Gene Dev. 16:3074–3086. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Orian-Rousseau V, Morrison H, Matzke A, et
al: Hepatocyte growth factor-induced Ras activation requires ERM
proteins linked to both CD44v6 and F-actin. Mol Biol Cell.
18:76–83. 2007. View Article : Google Scholar :
|
|
13
|
Orian-Rousseau V: CD44, a therapeutic
target for metastasising tumours. Eur J Cancer. 46:1271–1277. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cruz MC, Pereira AL, Lopes FF, et al:
Immunohistochemical expression of E-cadherin and CD44v6 in squamous
cell carcinomas of the lower lip and tongue. Braz Dent J. 20:64–69.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng XX, Wang ZC, Chen XY, et al:
Frequent loss of membranous E-cadherin in gastric cancers: A
cross-talk with Wnt in determining the fate of beta-catenin. Clin
Exp Metastasis. 22:85–93. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Todaro M, Gaggianesi M, Catalano V, et al:
CD44v6 is a marker of constitutive and reprogrammed cancer stem
cells driving colon cancer metastasis. Cell Stem Cell. 14:342–356.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yingling JM, Blanchard KL and Sawyer JS:
Development of TGF-beta signalling inhibitors for cancer therapy.
Nat Rev Drug Discov. 3:1011–1022. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siegel PM, Shu W, Cardiff RD, Muller WJ
and Massagué J: Transforming growth factor beta signaling impairs
Neu-induced mammary tumorigenesis while promoting pulmonary
metastasis. Proc Natl Acad Sci USA. 100:8430–8435. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao H, Ashihara E and Maekawa T: Targeting
the Wnt/β-catenin signaling pathway in human cancers. Expert Opin
Ther Targets. 15:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Daniels DL and Weis WI: Beta-catenin
directly displaces Groucho/TLE repressors from Tcf/Lef in
Wnt-mediated transcription activation. Nat Struct Mol Biol.
12:364–371. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamamichi K, Uehara Y, Kitamura N, Nakane
Y and Hioki K: Increased expression of CD44v6 mRNA significantly
correlates with distant metastasis and poor prognosis in gastric
cancer. Int J Cancer. 79:256–262. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Misra S, Ghatak S, Patil N, et al: Novel
dual cyclooxygenase and lipoxygenase inhibitors targeting
hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer
cells. Bioorg Med Chem. 21:2551–2559. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yanamoto S, Yamada S, Takahashi H, et al:
Expression of the cancer stem cell markers CD44v6 and ABCG2 in
tongue cancer: effect of neoadjuvant chemotherapy on local
recurrence. Int J Oncol. 44:1153–1162. 2014.PubMed/NCBI
|
|
24
|
Wang H, Rana S, Giese N, Büchler MW and
Zöller M: Tspan8, CD44v6 and alpha6 beta4 are biomarkers of
migrating pancreatic cancer-initiating cells. Int J Cancer.
133:416–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Afify AM, Tate S, Durbin-Johnson B, Rocke
DM and Konia T: Expression of CD44s and CD44v6 in lung cancer and
their correlation with prognostic factors. Int J Biol Markers.
26:50–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Klatte T, Seligson DB, Rao JY, et al:
Absent CD44v6 expression is an independent predictor of poor
urothelial bladder cancer outcome. J Urol. 183:2403–2408. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Crispn JC, Keenan BT, Finnell MD, et al:
Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased
on T cells from patients with systemic lupus erythematosus and is
correlated with disease activity. Arthritis Rheum. 62:1431–1437.
2010. View Article : Google Scholar
|
|
28
|
Shi Jm, Zhou Z, Wen Di and Li N:
Correlation of CD44v6 expression with ovarian cancer progression
and recurrence. BMC Cancer. 13:1822013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zöller M: CD44: can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar
|
|
31
|
Fuxe J and Karlsson MC: TGF-β-induced
epithelial-mesenchymal transition: a link between cancer and
inflammation. Semin Cancer Biol. 22:455–461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zantek ND, Azimi M, Fedor-Chaiken M, Wang
B, Brackenbury R and Kinch MS: E-cadherin regulates the function of
the EphA2 receptor tyrosine kinase. Cell Growth Differ. 10:629–638.
1999.PubMed/NCBI
|
|
33
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
